JP2004501079A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501079A5 JP2004501079A5 JP2001576772A JP2001576772A JP2004501079A5 JP 2004501079 A5 JP2004501079 A5 JP 2004501079A5 JP 2001576772 A JP2001576772 A JP 2001576772A JP 2001576772 A JP2001576772 A JP 2001576772A JP 2004501079 A5 JP2004501079 A5 JP 2004501079A5
- Authority
- JP
- Japan
- Prior art keywords
- sequelae
- pharmaceutically acceptable
- acceptable salt
- active ingredient
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003839 salts Chemical class 0.000 description 18
- AHZPJIGLXKMUCO-UHFFFAOYSA-N 2-amino-2-phenoxyacetamide Chemical class NC(=O)C(N)OC1=CC=CC=C1 AHZPJIGLXKMUCO-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 108060001061 calbindin Proteins 0.000 description 6
- 102000014823 calbindin Human genes 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 4
- 206010019196 Head injury Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- -1 aminophenoxyacetamide acetamide derivative Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000112100 | 2000-04-13 | ||
| PCT/JP2001/003198 WO2001079170A2 (en) | 2000-04-13 | 2001-04-13 | Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004501079A JP2004501079A (ja) | 2004-01-15 |
| JP2004501079A5 true JP2004501079A5 (enExample) | 2007-04-26 |
Family
ID=18624324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001576772A Abandoned JP2004501079A (ja) | 2000-04-13 | 2001-04-13 | アミノフェノキシアセタミド誘導体並びにそれらを含む医薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7067533B2 (enExample) |
| EP (1) | EP1228367B1 (enExample) |
| JP (1) | JP2004501079A (enExample) |
| KR (1) | KR100853968B1 (enExample) |
| CN (1) | CN1264821C (enExample) |
| AT (1) | ATE374366T1 (enExample) |
| AU (1) | AU784930B2 (enExample) |
| CA (1) | CA2370487A1 (enExample) |
| DE (1) | DE60130628T2 (enExample) |
| ES (1) | ES2291308T3 (enExample) |
| HU (1) | HUP0203383A3 (enExample) |
| WO (1) | WO2001079170A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
| JP2005508907A (ja) * | 2001-09-14 | 2005-04-07 | ノボ ノルディスク アクティーゼルスカブ | ヒスタミンｈ３受容体に選択的に結合する置換されたピペリジン |
| AU2006333522A1 (en) * | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf. | Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation |
| DE102005062990A1 (de) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln |
| SI2151439T1 (sl) * | 2007-04-27 | 2014-05-30 | Daiichi Sankyo Company, Limited | Nitrogeniran aromatski derivat s 6-členskim obročem in farmacevtsko sredstvo, ki obsega ta derivat |
| US20180305334A1 (en) * | 2015-10-14 | 2018-10-25 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| KR20190015748A (ko) | 2016-06-08 | 2019-02-14 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Atf4 경로 억제제로서의 화학적 화합물 |
| CN111285820A (zh) * | 2018-12-07 | 2020-06-16 | 成都康弘药业集团股份有限公司 | 一种枸橼酸莫沙必利有关物质及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW204411B (enExample) * | 1991-06-05 | 1993-04-21 | Tokyo Electron Co Ltd | |
| EP0982026B1 (en) | 1998-08-18 | 2006-05-17 | F. Hoffmann-La Roche Ag | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers |
| CN1198613C (zh) | 1998-10-16 | 2005-04-27 | 第一三得利制药株式会社 | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 |
-
2001
- 2001-04-13 AU AU48762/01A patent/AU784930B2/en not_active Ceased
- 2001-04-13 EP EP01921835A patent/EP1228367B1/en not_active Expired - Lifetime
- 2001-04-13 JP JP2001576772A patent/JP2004501079A/ja not_active Abandoned
- 2001-04-13 AT AT01921835T patent/ATE374366T1/de not_active IP Right Cessation
- 2001-04-13 WO PCT/JP2001/003198 patent/WO2001079170A2/en not_active Ceased
- 2001-04-13 DE DE60130628T patent/DE60130628T2/de not_active Expired - Fee Related
- 2001-04-13 KR KR1020017015979A patent/KR100853968B1/ko not_active Expired - Fee Related
- 2001-04-13 CN CNB018009085A patent/CN1264821C/zh not_active Expired - Fee Related
- 2001-04-13 HU HU0203383A patent/HUP0203383A3/hu unknown
- 2001-04-13 ES ES01921835T patent/ES2291308T3/es not_active Expired - Lifetime
- 2001-04-13 US US10/009,566 patent/US7067533B2/en not_active Expired - Fee Related
- 2001-04-13 CA CA002370487A patent/CA2370487A1/en not_active Abandoned
-
2006
- 2006-01-24 US US11/337,664 patent/US20060178401A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2438991A1 (en) | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| JP2019059760A5 (enExample) | ||
| WO2005079802A8 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| JP5837726B1 (ja) | アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤 | |
| JP2005502680A5 (enExample) | ||
| JP2008545793A5 (enExample) | ||
| JP2006507220A5 (enExample) | ||
| JP2002520416A5 (enExample) | ||
| JPWO1993011765A1 (ja) | （＋）アポビンカミン酸２−ニトロキシエチルエステルの新規な用途 | |
| JP2007500238A5 (enExample) | ||
| EP1621195A3 (en) | The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury | |
| TW200635903A (en) | Therapeutic agents | |
| JP2002524498A (ja) | 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用 | |
| CA2303815A1 (en) | N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain | |
| JP2004501079A5 (enExample) | ||
| JP2019512469A5 (enExample) | ||
| JP2005508872A5 (enExample) | ||
| TW200509933A (en) | Therapeutic agents | |
| WO2003094854A3 (en) | Succinoyl aminopyrazoles and related compounds | |
| JP2001523716A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2003505378A5 (enExample) | ||
| TW200635589A (en) | Therapeutic agents | |
| EP0543919A1 (en) | USE OF HETEROCYCLIC AMINO ALCOHOL COMPOUNDS FOR THE TREATMENT OF CNS DISEASES. | |
| JP2020533402A5 (enExample) |